Liver cancer
Conditions
Interventions
Case series:camrelizumab combined with TACE
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily joined the study, signed informed consent, good compliance, and follow-up; 2. Comply with the clinical diagnostic criteria of the 2017 edition of the standard diagnosis and treatment of primary liver cancer or the diagnosis of hepatocellular carcinoma by histopathology or cytology; 3. Aged greater than 18 years; 4. The investigator determined that the patient could receive carellizumab plus TACE; 5. The main organs function normally, without serious blood, heart, lung, liver, kidney dysfunction and immunodeficiency diseases; 6. Patient must have at least one measurable lesion per mRECIST at baseline; 7. The imaging evaluation method chooses enhanced CT or MRI.
Exclusion criteria
Exclusion criteria: 1. The subject has an immunodeficiency disease or medical history, or has a history of organ transplantation; 2. Pregnant or lactating women; 3. Patients who are not eligible for inclusion in this study are judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;DCR;OS;AE; | — |
Countries
China
Contacts
Public ContactGuowen Yin
Outcome results
None listed